Epoxide Hydrolase
Epoxide hydrolases (EH) present in all living organisms. The mammalian soluble epoxide hydrolase (sEH) is a 120 kDa dimer of two identical 62.5 kDa monomers arranged in an anti-parallel fashion. It is mostly expressed in the liver, kidneys, brain, endothelium, and at lesser levels in other tissues. Inflammation and pain are major components of many disease states. Mammalian sEH inhibition reduces blood pressure, inflammation and pain. The anti-inflammatory activities of sEH inhibitors occur in part through the NF-κB mediated down-regulation of COX2 transcription, resulting in lower production of pro-inflammatory prostaglandins such as PGE2 and PGD2.
All Product Categories
-
Epoxide Hydrolase Related Products (94)
Related Products (94)
-
Antibodies (1)
-
sEH/PPARδ modulator 1
0 ImagesCat. No.: HY-178332sEH/PPARδ modulator 1 is a sEH/PPARδ dual modulator. sEH/PPARδ modulator 1 can inhibit sEH with an IC50 of 0.46 μM and activate PPARδ with an EC50 of 0.12 μM. sEH/PPARδ modulator 1 can be used for the researches of inflammation, metabolic and cardiovascular disease.
-
sEH-IN-25
0 ImagesCat. No.: HY-184799CAS No.: 1141896-04-9sEH-IN-25 is an orally active soluble epoxide hydrolase (epoxide hydrolase) inhibitor, with an IC50 of 0.5 nM against human sEH and an IC50 of 2 nM against rat sEH. sEH-IN-25 can be used in the research of cardiovascular diseases.
-
Alisol B (Standard)
0 ImagesCat. No.: HY-N0805ARCAS No.: 18649-93-9Alisol B (Standard) is the analytical standard of Alisol B (HY-N0805A). This product is intended for research and analytical applications. Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a Ki of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G1 phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer.
-
sEH-IN-3
0 ImagesCat. No.: HY-174327sEH-IN-3 (Compound 50) is a soluble epoxide hydrolase (sEH) inhibitor (IC50: 0.46 nM). sEH-IN-3 can maintain the anti-inflammatory and analgesic activities of epoxyeicosatrienoic acids (EETs).
-
Soluble epoxide hydrolase inhibitor
0 ImagesCat. No.: HY-U00453CAS No.: 1241826-88-9Soluble epoxide hydrolase inhibitor is an inhibitor of soluble epoxide hydrolase, and inhibits human soluble epoxide hydrolase (h-sEH) with pIC50 of 8.4, extracted from patent WO 2010096722 A1, example 57.
-
sEH-IN-26
0 ImagessEH-IN-26 is a urea structure-based soluble epoxide hydrolase (sEH) inhibitor with selectivity for mammalian cytosolic and peroxisomal sEH. sEH-IN-26 can be used for the research of inflammation and epoxide hydrolase-related diseases.
-
Valpromide (Standard)
0 ImagesValpromide (Standard) is the analytical standard of Valpromide (HY-B2117). This product is intended for research and analytical applications. Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle.
-
AUDA (Standard)
0 ImagesCat. No.: HY-108570RCAS No.: 479413-70-2AUDA (Standard) is the analytical standard of AUDA. This product is intended for research and analytical applications. AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively. AUDA has anti-inflammatory activity.
-
(±)10(11)-EpDPA
0 ImagesCat. No.: HY-126041ACAS No.: 895127-65-8Synonyms: (±)10,11-EDP; (±)10,11-EpDPE; (±)10,11-Epoxy docosapentaenoic acid(±)10(11)-EpDPA, a docosahexaenoic acid epoxygenase metabolite, acts as a substrate for soluble epoxide hydrolase (sEH) with a Km value of 5.1 µM for human sEH.
-
LQ-38
0 ImagesCat. No.: HY-168211LQ-38 is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC50 of 5.2 nM. LQ-38 exhibits anti-inflammatory activity in rat foot edema model and mouse acute pancreatitis model, exhibits analgesic effect in Acetic acid (HY-Y0319)-induced writhing mouse model.
-
CUDA-d11
0 ImagesCat. No.: HY-121538SCUDA-d11 is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease.
-
AR-9281 (Standard)
0 ImagesSynonyms: APAU (Standard)AR-9281 (Standard) is the analytical standard of AR-9281. This product is intended for research and analytical applications. AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes.
